Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Sarcoidosis Vasc Diffuse Lung Dis ; 33(3): 196-200, 2016 Oct 07.
Article in English | MEDLINE | ID: mdl-27758983

ABSTRACT

BACKGROUND: Sarcoidosis is a granulomatous systemic disease of unknown aetiology. The diagnosis needs histological confirmation of the presence of non-caseating granulomata. One option is a conjunctival biopsy. The aims of this study were to evaluate conjunctival biopsy for the diagnosis of sarcoidosis with respect to its sensitivity and to assess its cost effectiveness by comparison with other histopathological diagnostic procedures. METHODS: Patients were identified from the database of the Interstitial Lung Disease Clinic (ILDC) of the Chest Department of Ege University Hospital from May 2008 to June 2014.  The patients who had biopsy procedures performed for the definitive diagnosis of sarcoidosis were assessed. Their diagnostic procedures and the cost of procedures were recorded. The cost per positive result for each procedure was calculated.  Results: In total, 280 patients were followed up with a diagnosis of sarcoidosis, of whom 174 had histological confirmation; these constitute the study population. There were 127 females and 47 males with a median age of 46 years (range 14-78 years). Forty three patients had conjunctival biopsy and we could establish a diagnosis in 54% of these by means of conjunctival biopsy. Moreover, we showed that this biopsy can provide positive result for sarcoidosis patients who lack abnormal eye findings. Additionally, it is cost effective approach and without complications. CONCLUSION: This study re-asserts the value of  conjunctival biopsy, which was described in the past but is not commonly used nowadays. In the presence of suggestive clinic and radiologic findings, we recommend conjunctival biopsy as the first choice for the histopathological confirmation of sarcoidosis.


Subject(s)
Biopsy , Conjunctiva/pathology , Conjunctival Diseases/diagnosis , Sarcoidosis/diagnosis , Adolescent , Adult , Aged , Biopsy/economics , Conjunctival Diseases/economics , Conjunctival Diseases/pathology , Cost-Benefit Analysis , Databases, Factual , Female , Hospital Costs , Hospitals, University , Humans , Male , Middle Aged , Predictive Value of Tests , Reproducibility of Results , Sarcoidosis/economics , Sarcoidosis/pathology , Turkey , Young Adult
2.
Curr Med Res Opin ; 27(10): 1949-58, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21878000

ABSTRACT

BACKGROUND: Lowering intraocular pressure (IOP) is currently the only therapeutic approach that preserves visual function in primary open-angle glaucoma. In making treatment decisions for first- and second-line therapy, the clinician needs to provide an appropriate balance of efficacy and tolerability. Prostaglandin analogues (PGAs) are frequently used as first-line monotherapy, because of their efficacy and low risk of systemic side effects. Similarly, PGA-based fixed combinations are frequently used in patients who progress or fail to achieve the target IOP. SCOPE: We have reviewed the literature on the management of primary open-angle glaucoma with PGAs, both as monotherapies and in fixed combinations. FINDINGS: In the clinical trial and meta-analysis data identified, bimatoprost 0.03% seems to be associated with a greater overall ability to lower IOP compared with latanoprost, travoprost or tafluprost, at the cost of a slightly higher incidence of conjunctival hyperaemia. Studies indicate that patients' adherence to treatment is generally better with PGAs than with many other monotherapies. In patients requiring more than one IOP-lowering agent, fixed combination treatments may provide improved adherence and tolerability benefits compared with concomitant use of individual treatments. Bimatoprost/timolol fixed combination appears to be slightly more efficacious than latanoprost/timolol or travoprost/timolol, and tolerability differences between the fixed combinations appear to be slight, probably because the addition of timolol to the PGA component lessens the associated hyperaemia. Surveys on EU physician attitudes appear largely in line with these clinical data. CONCLUSION: An appropriate balance between efficacy and tolerability ensures optimum IOP lowering and reduces the risk of non-adherence. PGAs largely fulfil this need as monotherapies and as components of combinations.


Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Glaucoma, Open-Angle/drug therapy , Prostaglandins F, Synthetic/therapeutic use , Timolol/therapeutic use , Adrenergic beta-Antagonists/adverse effects , Adrenergic beta-Antagonists/economics , Conjunctival Diseases/chemically induced , Conjunctival Diseases/economics , Conjunctival Diseases/physiopathology , Drug Therapy, Combination/methods , Glaucoma, Open-Angle/economics , Glaucoma, Open-Angle/physiopathology , Humans , Hyperemia/chemically induced , Hyperemia/economics , Hyperemia/physiopathology , Patient Compliance , Prostaglandins F, Synthetic/adverse effects , Timolol/adverse effects , Timolol/economics
SELECTION OF CITATIONS
SEARCH DETAIL
...